1. Home
  2. LTRN vs FEMY Comparison

LTRN vs FEMY Comparison

Compare LTRN & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

N/A

Current Price

$0.29

Market Cap

10.0M

Sector

Health Care

ML Signal

N/A

Logo Femasys Inc.

FEMY

Femasys Inc.

N/A

Current Price

$1.24

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTRN
FEMY
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LTRN
FEMY
Price
$0.29
$1.24
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
★ $17.50
$14.75
AVG Volume (30 Days)
★ 166.9K
97.3K
Earning Date
11-17-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
18.65
★ 44.71
EPS
★ N/A
N/A
Revenue
N/A
★ $2,293,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$294.61
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40.77
52 Week Low
$0.36
$0.29
52 Week High
$4.34
$6.29

Technical Indicators

Market Signals
Indicator
LTRN
FEMY
Relative Strength Index (RSI) 20.94 35.41
Support Level N/A $0.37
Resistance Level $0.84 $1.55
Average True Range (ATR) 0.08 0.14
MACD -0.00 0.01
Stochastic Oscillator 0.07 31.25

Price Performance

Historical Comparison
LTRN
FEMY

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: